^
Association details:
| Biomarker: | NRAS G12D |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | BAY 1125976 (AKT1 inhibitor, AKT2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models
Excerpt:
Daily treatment of 25 or 50 mg/kg BAY 1125976 demonstrated statistically significant efficacy in the androgen‐dependent LAPC‐4 (AKT1E17K; NRASG12D) prostate cancer model...
DOI:
https://doi.org/10.1002/ijc.30457
